Introduction: Regulatory B Cell Special Issuemaking all the pieces fit Thomas F. Tedder
Associate Editor B cells positively regulate immune responses and inflammation through antibody production and antigen presentation for optimal CD4 + T-cell activation (1) . However, specific and functionally important B-cell subsets with negative regulatory properties have been recently identified that contribute to immunological tolerance by down-modulating immune responses under homeostatic, as well as inflammatory and pathogenic, conditions. This Special Issue focuses on regulatory B-cell subsets that suppress disease symptoms in experimental autoimmune encephalitis (EAE), chronic colitis, contact hypersensitivity [delayed type hypersensitivity (DTH)], collagen-induced arthritis, allergy, infection, lupus and non-obese diabetic mouse models, and other B-cell subsets that augment acute and chronic inflammation. Despite their short tenure on the immunology stage, regulatory B cells have garnered considerable attention as important components of the cellular network that modulates the immune system.
The concept of regulatory B cells first appeared in the literature before the identification of phenotypically distinct B-cell subsets. B-cell suppression of immune activation was first identified during DTH responses in guinea pigs in 1974 (2, 3) . These studies introduced the concept that 'suppressor B cells' could regulate T-cell function, but this notion and the parallel belief in 'suppressor T cells' eventually fell from favor. However, Wolf et al. re-established this concept when they demonstrated in 1996 that the disease course of EAE was prolonged in B-cell-deficient mice (4). Mizoguchi et al. subsequently demonstrated a suppressive role for B cells in chronic colitis in 1997 and were the first to publish the term 'regulatory B cells' in 2002 to designate B cells that regulate immune responses by secreting IL-10 (5, 6) . These studies were accompanied by numerous provocative papers from 2000 to 2008 that demonstrated B-cell regulatory effects on diverse autoimmune responses (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . These and other papers at the time documented the existence of regulatory B cells and repeatedly observed that IL-10 was central to their regulatory function. Despite this, the phenotype, functions and molecular characteristics of regulatory B cells have remained complicated and are becoming even more diverse.
In large part, uncertainty within the regulatory B-cell field reflects an evolution of knowledge inherent to cutting-edge basic biomedical research. Diverse laboratories approaching the same issue from different perspectives commonly generate confusion within the literature early in the discovery process until observations are sufficiently validated and enough knowledge is gained to fit the puzzle pieces together. This pattern of scientific evolution was clearly displayed when the biology of regulatory T cells first came into focus, and remnants of uncertainty remain. Even now, our current appreciation of the functional diversity within the B-cell lineage is likely to be naive. Nonetheless, the chapters within this Special Issue on regulatory B cells collectively highlight the fact that B cells are functionally diverse as a population, as is now appreciated for T-cell subsets.
Heterogeneity of the B-cell antigen receptor (BCR) and cell surface receptors unquestionably contributes to the observed functional diversity among B-cell populations. The current literature also suggests that B cells have the capacity to produce a variety of cytokines and inflammatory mediators, including IL-2, IL-3, IL-4, IL-6, IL-10, IL-12, IL-17, IL-33, IL-35, GM-CSF, IFN-γ and TNF, but the extent to which these are expressed by individual or overlapping B cells needs to be determined. Further studies are also needed to document the reality of this diversity, as contaminating cells within B-cellenriched populations may have contributed transcripts/ proteins in some cases, and the natural expression of other cytokines has been difficult to establish in any cell population. Thus, future studies are needed to validate one-off observations, findings from single laboratories, and to better understand those observations that are consistent across numerous groups in order to yield a more complete picture of how variably defined B-cell subsets regulate immune responses.
In an effort to illustrate the current state of the regulatory B-cell field, nine groups of investigators have collaborated to generate this issue by providing their independent perspectives on specific topics within the field. This Special Issue also illustrates the reality that the term 'regulatory B cell' as it is currently used in the literature is likely to circumscribe a wide collection of functionally distinct B-cell subsets with potent regulatory effects. For example, although IL-10 production is commonly associated with 'regulatory B cells' and is frequently assumed to be their mechanism of negative regulation, some groups have identified populations of B cells with IL-10-independent regulatory functions. As no specific phenotypic markers, signaling molecules or transcription factors have been identified to delineate among regulatory B-cell subsets, the functionally important cytokines or cell surface molecules that drive their regulatory function currently offer the best means to identify specific B-cell subsets with different functional properties (18) . Thus, regulatory cells do not appear to represent specific lineages within the B-cell population but may delimit B cells that have acquired distinct functional abilities in response to their environmental cues. Jacquelyn Lykken, Kathleen Candando and Thomas Tedder (p. 471) outline the concept that the capacity of B cells to produce IL-10 should be used as the exclusive marker for the regulatory B-cell subset known as B10 cells (19) . By contrast, Claudia Mauri and Madhvi Menon (p. 479) subdivide phenotypically defined B-cell sub-populations into numerous 'Breg' subsets (20) . As the regulatory B-cell puzzle is completed at the cellular and molecular levels, the relative value of these two complementary approaches to identifying regulatory B cells and their functions should become apparent.
Yoshihiro Baba, Masanori Matsumoto and Tomohiro Kurosaki (p. 487) outline the cellular signaling components controlling IL-10-dependent regulatory B-cell function in the context of the development of different B-cell subsets (21) . Multiple lines of evidence indicate that BCR-associated, TLRdependent and cell surface receptor and cytokine receptor signaling pathways contribute to regulatory B-cell development and function (22, 23) . For example, IL-21 and potentially IL-35 are critically important for inducing B-cell IL-10 production (24) (25) (26) (27) . In addition, some regulatory B cells identified by expression of the T-cell immunoglobulin mucin 1 (TIM-1) molecule can be maintained by and induced through TIM-1 ligation to promote tolerance in mice (28) (29) (30) (31) . Synthetic linked cytokine 'fusokines', including GM-CSF linked to MCP3 (CCL7), can generate IL-10-dependent B(GMME3) regulatory B cells as can GM-CSF fused with IL-15 (GIFT15), which skews B cells toward regulatory GIFT15 B(reg) or iBreg cells (32, 33) . However, these and other pathways are common to most other B-cell subsets, highlighting the difficulty in identifying signals that are exclusive to regulatory B-cell function versus overall B-cell development, survival and localization. Identifying the cell surface molecules, signaling pathways and transcription factors that control the expression of IL-10 and other effector molecules will help clarify the molecular pathways that lead to divergent regulatory B-cell functions.
The importance of regulatory B cells is demonstrated by the discovery of parallel B cells in humans. Tomomitsu Miyagaki, Manabu Fujimoto and Shinichi Sato (p. 495) review the significance of regulatory B cells in mouse models of disease and extend these findings to what has been described in humans (34) . Even though B-cell development and functional studies are more complicated in humans than mice, new publications characterizing human regulatory B-cell subsets are becoming common. In vitro studies suggest an essential role for IL-10 in inducing an immunoregulatory phenotype in B cells that exert substantial anti-inflammatory and immunosuppressive functions (35, 36) , with IgG4 production confined to regulatory B cells that suppress antigen-specific immune responses and chronic graft-versus-host disease (37, 38) . Mohini Gray and David Gray (p. 505) discuss the pivotal role that autoantigens exposed by apoptotic cells play in stimulating IL-10 production in mouse and human B cells (39) . These and other chapters indicate the future potential of therapies that target human regulatory B cells for inflammatory and autoimmune diseases, a possibility predicated on the consistently impressive results obtained in preclinical studies in mice. Although the dynamic changes in regulatory B-cell numbers described in the literature during human disease foretell their importance in disease regulation, the true extent to which human regulatory B cells can be manipulated for therapeutic benefit will only be revealed when targeted drugs and therapies directed at regulatory B cells are employed in the clinic, a critical goal for the entire field.
In addition to regulating autoimmunity, Ping Shen and Simon Fillatreau (p. 513) evaluate the effect of regulatory B cells on host defense against pathogens, including bacteria, helminths and viruses (40) . While inhibiting B-cell responses to infectious agents, some infections also elicit IL-10-producing regulatory B cells that shape the course and magnitude of adaptive, cellular, humoral and innate immune responses (41, 42) . Shen and Fillatreau postulate that regulatory cells in turn blunt concurrent immune responses directed toward unrelated antigens in a bystander manner and, as a consequence, ameliorate the course of autoimmune or allergic airway inflammation as described by others (43, 44) .
Yu Zhang, Nicolas Gallastegui and Joseph Rosenblatt (p. 521) review how immunosuppressive B-cell sub-populations migrate into tumor sites and acquire a regulatory phenotype, eventually leading to attenuation of the local antitumor immune response (45) . Tumor-evoked regulatory B cells (tBreg cells) promote cancer metastasis and escape from the immune system by converting resting CD4 + T cells to regulatory T cells (46, 47) . Killer effector B cells represent another subset of CD5 + regulatory B cells that are regulated by IL-10 to induce antigen-specific immune tolerance and directly kill tumor cells by secreting Fas-ligand + exosomes (48) (49) (50) . Thus, manipulation of different regulatory B-cell subsets may eventually provide pathways for modulating immune responses to pathogens, as well as hematopoietic and solid tumors.
Although B10 cells or IL-10-producing regulatory B cells appear to account for a substantial portion of regulatory B-cell function, it is now clear that additional molecularly distinct regulatory B-cell subsets with other unique properties have pivotal roles in tolerance regulation. The chapter by Avijit Ray, Luman Wang and Bonnie Dittel (p. 531) explores these populations (51) . As one example, after Janeway et al. demonstrated that the disease course of EAE was prolonged in B-cell-deficient mice (4), studies by Dittel et al. have shown that B cells can influence this process through IL-10independent mechanisms (52, 53) . PD-L1 hi regulatory B cells are also critical regulators of humoral immunity (54) . Benjamin Chousterman and Filip Swirski (p. 537) further document the existence of additional B-cell subsets and also show that a subset of CD5 + B1a cells termed innate response activator (IRA) B cells produce GM-CSF and IL-3 (55) . In contrast with most other regulatory B-cell subsets, IRA B cells contribute to host immune responses by producing polyreactive IgM and amplifying inflammation. Human B cells also differentiate into granzyme B-expressing regulatory B cells (GraB cells) following incomplete T-cell help (56, 57) . GraB cells are phenotypically and functionally distinct from B10 cells and they do not express IL-10, but instead negatively regulate T-cell proliferative responses through cytotoxic granzyme B-dependent mechanisms. GraB cells can be found in early HIV infection (57) and in patients with lupus and other autoimmune diseases (58) , and they function during early cellular immune responses including tumor immunosurveillance (59) . Thus, the existence of both negative and positive regulatory B-cell subsets has been well documented in the literature.
With the exception of their functionally important cytokines or cell surface molecules that yield immunoregulatory function, no molecular markers exclusively define specific regulatory B-cell subsets. Most regulatory B-cell studies have thus used unfractionated, phenotypically defined or mixed B-cell sub-populations, which likely masks the degree of B-cell heterogeneity within most functionally defined B-cell subpopulations and may have also introduced potential biases into the model systems being evaluated. B cells from different stages of activation or tissue locations such as transitional, marginal zone, peritoneal cavity or plasma cell stages of differentiation are also proposed to acquire overlapping regulatory functions. However, these phases are frequently defined by relatively limited phenotypic markers rather than a bona fide developmental state, anatomic location within tissues or the functional capacity of the cells. Thereby, these subsets frequently represent heterogeneous mixtures of B cells. As a result, the true diversity of regulatory B-cell subsets may be smaller than currently described and may instead define B cells that have gained distinct functional programs in response to their specific BCR, other cell surface receptors or environmental cues.
Although it may be premature to develop a unified nomenclature for each B-cell subset at this point in time because of the rapidly increasing appreciation of B-cell heterogeneity, the existence of multiple molecularly distinct B cells with different regulatory activities suggests that the term 'regulatory B cells' broadly describes multiple classes of B cells instead of a homogenous B-cell subset. This heterogeneity is reflected in the current terminology for different regulatory B-cell subsets within the chapters of this special edition, which now includes B10 cells, Breg cells, Br1 cells, B(GMME3) cells, GIFT15 B(reg) cells, GraB cells, i35-Breg cells, iBreg cells, IRA B cells, killer B cells, suppressor B cells and tBreg cells, as well as large numbers of phenotypically defined B-cell subsets.
The future will undoubtedly lead to the identification of additional B-cell subsets with regulatory activities, which is anticipated to reveal a significant degree of functional diversity within the B-cell lineage. Eventually, discussions of the B-cell effector repertoire will not just focus on the diversity of BCR sequences within the B-cell population but may also consider the diversity of B-cell functions. The molecular dissection of each of these functional programs and regulatory cell processes should eventually coalesce to reduce the current level of confusion within the field and piece together the complete regulatory B-cell puzzle.
